Targeted ultrasound contrast agents: Diagnostic and therapeutic potential

Research output: Chapter in Book/Report/Conference proceedingConference contribution

6 Citations (Scopus)

Abstract

Future clinical applications of contrast-enhanced ultrasound will likely expand beyond the assessment of microvascular perfusion. One promising direction is the development of the field of "molecular imaging" with microbubbles or other ultrasound contrast agents. This application contrast-enhanced ultrasound requires the development of site-targeted contrast agents that are retained within regions of a specific disease process, thereby allowing phenotypic characterization of tissue. Since microbubbles are pure intravascular tracers, the disease processes to be assessed must be characterized by unique antigens or "fingerprints" that are expressed within the vascular compartment. Accordingly, the pathologic states that have been or will be imaged include inflammation, atherosclerosis, neoplasms, thrombus formation, and angiogenesis,; all of which are initiated and supported by molecular events within the vascular space. This review describes: 1) different strategies that have been employed to direct microbubbles to regions of disease, 2) the unique challenges for imaging targeted ultrasound contrast agents, and 3) some of the early experience imaging molecular events in animal models of disease.

Original languageEnglish (US)
Title of host publicationProceedings of the IEEE Ultrasonics Symposium
Pages1695-1703
Number of pages9
Volume2
StatePublished - 2001
Externally publishedYes
Event2001 Ultrasonics Symposium - Atlanta, GA, United States
Duration: Oct 6 2001Oct 10 2001

Other

Other2001 Ultrasonics Symposium
CountryUnited States
CityAtlanta, GA
Period10/6/0110/10/01

Fingerprint

Ultrasonics
Molecular imaging
Antigens
Animals
Tissue
Imaging techniques

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Lindner, J. (2001). Targeted ultrasound contrast agents: Diagnostic and therapeutic potential. In Proceedings of the IEEE Ultrasonics Symposium (Vol. 2, pp. 1695-1703)

Targeted ultrasound contrast agents : Diagnostic and therapeutic potential. / Lindner, Jonathan.

Proceedings of the IEEE Ultrasonics Symposium. Vol. 2 2001. p. 1695-1703.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Lindner, J 2001, Targeted ultrasound contrast agents: Diagnostic and therapeutic potential. in Proceedings of the IEEE Ultrasonics Symposium. vol. 2, pp. 1695-1703, 2001 Ultrasonics Symposium, Atlanta, GA, United States, 10/6/01.
Lindner J. Targeted ultrasound contrast agents: Diagnostic and therapeutic potential. In Proceedings of the IEEE Ultrasonics Symposium. Vol. 2. 2001. p. 1695-1703
Lindner, Jonathan. / Targeted ultrasound contrast agents : Diagnostic and therapeutic potential. Proceedings of the IEEE Ultrasonics Symposium. Vol. 2 2001. pp. 1695-1703
@inproceedings{be4d3987cc824bf69c82a68ca0a7b9f5,
title = "Targeted ultrasound contrast agents: Diagnostic and therapeutic potential",
abstract = "Future clinical applications of contrast-enhanced ultrasound will likely expand beyond the assessment of microvascular perfusion. One promising direction is the development of the field of {"}molecular imaging{"} with microbubbles or other ultrasound contrast agents. This application contrast-enhanced ultrasound requires the development of site-targeted contrast agents that are retained within regions of a specific disease process, thereby allowing phenotypic characterization of tissue. Since microbubbles are pure intravascular tracers, the disease processes to be assessed must be characterized by unique antigens or {"}fingerprints{"} that are expressed within the vascular compartment. Accordingly, the pathologic states that have been or will be imaged include inflammation, atherosclerosis, neoplasms, thrombus formation, and angiogenesis,; all of which are initiated and supported by molecular events within the vascular space. This review describes: 1) different strategies that have been employed to direct microbubbles to regions of disease, 2) the unique challenges for imaging targeted ultrasound contrast agents, and 3) some of the early experience imaging molecular events in animal models of disease.",
author = "Jonathan Lindner",
year = "2001",
language = "English (US)",
volume = "2",
pages = "1695--1703",
booktitle = "Proceedings of the IEEE Ultrasonics Symposium",

}

TY - GEN

T1 - Targeted ultrasound contrast agents

T2 - Diagnostic and therapeutic potential

AU - Lindner, Jonathan

PY - 2001

Y1 - 2001

N2 - Future clinical applications of contrast-enhanced ultrasound will likely expand beyond the assessment of microvascular perfusion. One promising direction is the development of the field of "molecular imaging" with microbubbles or other ultrasound contrast agents. This application contrast-enhanced ultrasound requires the development of site-targeted contrast agents that are retained within regions of a specific disease process, thereby allowing phenotypic characterization of tissue. Since microbubbles are pure intravascular tracers, the disease processes to be assessed must be characterized by unique antigens or "fingerprints" that are expressed within the vascular compartment. Accordingly, the pathologic states that have been or will be imaged include inflammation, atherosclerosis, neoplasms, thrombus formation, and angiogenesis,; all of which are initiated and supported by molecular events within the vascular space. This review describes: 1) different strategies that have been employed to direct microbubbles to regions of disease, 2) the unique challenges for imaging targeted ultrasound contrast agents, and 3) some of the early experience imaging molecular events in animal models of disease.

AB - Future clinical applications of contrast-enhanced ultrasound will likely expand beyond the assessment of microvascular perfusion. One promising direction is the development of the field of "molecular imaging" with microbubbles or other ultrasound contrast agents. This application contrast-enhanced ultrasound requires the development of site-targeted contrast agents that are retained within regions of a specific disease process, thereby allowing phenotypic characterization of tissue. Since microbubbles are pure intravascular tracers, the disease processes to be assessed must be characterized by unique antigens or "fingerprints" that are expressed within the vascular compartment. Accordingly, the pathologic states that have been or will be imaged include inflammation, atherosclerosis, neoplasms, thrombus formation, and angiogenesis,; all of which are initiated and supported by molecular events within the vascular space. This review describes: 1) different strategies that have been employed to direct microbubbles to regions of disease, 2) the unique challenges for imaging targeted ultrasound contrast agents, and 3) some of the early experience imaging molecular events in animal models of disease.

UR - http://www.scopus.com/inward/record.url?scp=0035729067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035729067&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:0035729067

VL - 2

SP - 1695

EP - 1703

BT - Proceedings of the IEEE Ultrasonics Symposium

ER -